AI

Charles River and Valence Discovery Declare Strategic Partnership to Provide AI-Enabled Drug Design Capabilities to Clients

Valence Discovery, Charles River | April 08, 2021

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement.

Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug up-and-comers in novel districts of compound space, trailed by quick streamlining against project-explicit strength, selectivity, security, and pharmacology rules. Valence has spearheaded the utilization of few-shot learning in drug configuration, permitting the organization to open forecast errands for which just modest quantities of preparing information are accessible, defeating a basic constraint of existing AI advances in drug revelation.

Banding together to Accelerate Discoveries

By consolidating top tier AI advances with Charles River's start to finish abilities, the coalition can possibly essentially speed up revelation endeavors from hit plan through lead improvement.

Through the cooperation, Charles River customers will have the alternative to get to Valence's foundation to help their medication revelation endeavors. When exploiting this alternative, customers can expect expanded variety in substance matter being examined, in mix with more fast improvement against complex, project-explicit plan measures, at last diminishing courses of events and improving achievement rates for drug revelation projects.

Affirmed Quotes

"This coordinated effort reflects Charles River's continuous obligation to improving our arrangement of creative innovation arrangements. We anticipate utilizing Valence's exceptional stage to improve results for our customers." – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River

"The Valence stage offers a stage change improvement over existing again plan advancements. We've been reliably intrigued by Valence Discovery's capacity to create top notch synthetic matter that is promptly synthesizable, in novel areas of compound space, from datasets not in any case open to AI strategies." – Grant Wishart, PhD, Director of Computer Aided Drug Design, Charles River

"We are excited to collaborate with Charles River, a worldwide pioneer trusted by numerous individuals of the world's top drug and biotech organizations. This cooperation is a significant advance in facilitating our central goal of engaging each medication disclosure researcher with the most recent developments in AI-empowered medication plan."– Daniel Cohen, CEO of Valence Discovery

About Valence's AI-Enabled Drug Design Platform

The Valence stage develops the scholarly community driving exploration done by the organization's establishing group at Mila, the world's biggest profound learning research foundation. Specifically, Valence has spearheaded the use of not many shot learning in drug configuration, permitting the organization to open forecast assignments for which just limited quantities of preparing information are accessible, including novel targets and complex ADME models, while additionally guaranteeing that AI-produced particles are of high therapeutic science quality and promptly synthesizable. Also, Valence utilizes dynamic learning and iterative improvement procedures to guarantee that lone the most data rich mixtures are chosen for amalgamation, empowering the plan of mixtures meeting the objective strength, selectivity, and ADME models in less emphasess, and with undeniably less information, than in any case conceivable.

About Valence Discovery
Valence is focused on opening the genuine capability of profound learning in drug plan by binding together top tier profound learning innovations with instinctive foundation to make these advances all the more extensively open to R&D associations, everything being equal. Valence's AI-empowered medication plan stage has been widely approved and is right now being utilized to distinguish and configuration drug applicants as a team with industry-driving accomplices. The organization is spearheading the utilization of few-shot learning in drug plan and is creating and conveying novel AI strategies for sub-atomic property expectation, generative science, and multiparameter advancement. Valence (once in the past InVivo AI) was established in 2018, is exhorted by profound learning pioneer, Dr. Yoshua Bengio, and is gladly settled in Montreal at Mila, the world's biggest profound learning research foundation, with an office in Cambridge, Mass.

About Charles River
Charles River gives fundamental items and administrations to help drug and biotechnology organizations, government offices and driving scholastic foundations all throughout the planet speed up their exploration and medication improvement endeavors. Our devoted workers are centered around giving customers precisely what they need to improve and assist the disclosure, beginning phase advancement and safe production of new treatments for the patients who need them.

Spotlight

For centuries, farmers have used tools, from plows to tractors, to turn over,
or till, their soil to remove weeds before planting. While this has been a
common and effective method for generations, it can ultimately lead to soil
erosion and loss of essential soil nutrients. Advances in biotech crops and
crop protection products are allowing farmers worldwide a new approach
through conservation – or no-till – agriculture. By leaving the soil untilled,
farmers build up the nutrients in their fields and preserve topsoil, which
boosts yields and helps our environment

Spotlight

For centuries, farmers have used tools, from plows to tractors, to turn over,
or till, their soil to remove weeds before planting. While this has been a
common and effective method for generations, it can ultimately lead to soil
erosion and loss of essential soil nutrients. Advances in biotech crops and
crop protection products are allowing farmers worldwide a new approach
through conservation – or no-till – agriculture. By leaving the soil untilled,
farmers build up the nutrients in their fields and preserve topsoil, which
boosts yields and helps our environment

Related News

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

Vedere Bio | October 29, 2020

Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million. Based on technology from the laboratories of Drs. Ehud Isacoff and John G. Flannery of UC Berkeley, and technology directed at enhanced ocular gene therapy delivery arising jointly between UC Berkeley and the School of Veterinary Medicine at the University of Pennsylvania, Vedere Bio was formed in the Atlas Venture incubator in June 2019. The company was launched with a $21 million Series A financing and began lab operations at LabCentral in Cambridge, MA where it advanced its lead programs from concept to development candidate within one year. Immediately prior to the acquisition, certain earlier-stage vision restoration and vision preservation assets leveraging the company's ocular gene therapy toolbox were spun out into a newly formed entity – Vedere Bio II, Inc.

Read More

MEDICAL

Duke Researchers Identify Genetic Mechanism in Brain Lesion Formation Using Single-Cell DNA Sequencing from Mission Bio

Mission Bio | March 15, 2022

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced new findings by Daniel Snellings from the lab of Douglas Marchuk, PhD, at Duke University School of Medicine using single-cell DNA sequencing to identify genetic mechanisms leading to the development of cerebral cavernous malformations (CCMs). The study, published today in the journal Nature Cardiovascular Research, is the latest demonstration of how Mission Bio's Tapestri Platform is allowing researchers to probe new aspects of biology at a single-cell resolution not possible with bulk sequencing. Dr. Marchuk is Professor of Molecular Genetics and Microbiology at Duke. CCMs, a blood vessel abnormality that can lead to brain hemorrhages, have long been associated with developmental venous anomalies (DVAs), a typically benign but irregular vascular arrangement often found near sporadic CCMs – though researchers had yet to prove a link. In the paper, Snellings and colleagues sequenced DNA from three CCM patient samples to see if somatic mutations in MAP3K3 or PIK3CA – common in patients with CCMs – co-existed in the same cells. Single-cell DNA sequencing with Tapestri found co-occurring mutations in the cells of all three samples, a pattern that could not be determined by bulk sequencing. Further, the group found that the CCMs and the associated DVAs harbored identical mutations in PIK3CA, but that mutations in MAP3K3 were only found in the CCMs. Because of the pattern of PIK3CA and MAP3K3 co-occurrence in CCMs, the team could assess the temporal pattern of genetic mutations associated with disease progression. They determined that DVA is the first lesion to occur, and that CCM development happens only after acquisition of an activating MAP3K3 mutation in a cell of the existing DVA.sazsz It was surprising to find that something as common as DVAs—which are present in up to 16% of people—could be caused by a cancer driver mutation. This explains why sporadic CCMs are often found in the vicinity of a DVA, and may explain why other diseases like pontine gliomas are also found near DVAs." Snellings. Tapestri is regularly deployed in cancer research to detect somatic mutations in clonal populations as a way of tracking tumor development, and the researchers adapted that methodology to evaluate the relationship between DVAs and CCMs. Since DVAs are not regularly biopsied, the researchers also confirmed the presence of circulating mRNAs in patients with both CCM and DVA related to this biological pathway, in plasma – a first step toward establishing a biomarker for CCM risk in patients with DVAs. We expect this research will have a meaningful impact for patients at risk for developing spontaneous cerebral cavernous malformations, which can lead to strokes or even death, This paper is a powerful new demonstration that there are many disease areas where single-cell DNA sequencing is helping elucidate the mechanisms of disease development, and identifying potential targets for diagnostics or therapeutics." Yan Zhang, PhD, CEO of Mission Bio. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio's multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others. The company's Tapestri platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer.

Read More

CELL AND GENE THERAPY

Biogen and Ginkgo Bioworks Collaborate and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

Biogen, Ginkgo Bioworks | May 22, 2021

Biogen and Ginkgo Bioworks announced a partnership in gene therapy today. The companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors by working together. Recombinant AAV-based vectors are extensively used in the development of novel gene therapies with the ability to cure neurological and neuromuscular diseases, as well as other conditions in a variety of therapeutic areas. Manufacturing is now time-consuming and expensive, making it difficult to develop therapies for diseases with high dosage requirements and large patient populations. Ginkgo intends to address these issues by using its mammalian cell programming platform to increase the performance of AAV-producing plasmid vectors and cell lines, potentially accelerating Biogen's development of novel gene therapies. “We believe that Ginkgo's unique combination of cell programming expertise, proprietary tools, and biological system awareness makes them a perfect collaborative partner to explore a broad range of design ideas to optimize constructs,” said Alphonse Galdes, Ph.D., Biogen's Head of Pharmaceutical Operations and Technology.“They share our goal of ensuring that approved therapies are not delayed due to manufacturing constraints and are available to patients all over the world.” “We are delighted to partner with Biogen as they seek to develop treatments that can potentially delay, stop, or cure neurological and neurodegenerative diseases, as well as to improve the industry standard for AAV manufacturing,” said Jason Kelly, CEO of Ginkgo Bioworks. “Synthetic biology is utilizing the power of living cells to develop the next generation of therapeutics, including CAR-T, CRISPR, and gene therapies, which we hope would have a significant effect on the lives of many people.” Biogen will have access to Ginkgo's proprietary cell programming platform and capabilities under the terms of the agreement. Ginkgo will use its bioengineering facilities and resources to improve Biogen's gene therapy manufacturing processes' AAV output titers. Ginkgo will receive a $5 million initial payment and will be eligible for milestone payments of up to $115 million if the partnership programs achieve certain research, development, and commercial milestones. About Biogen Our mission at Biogen is clear: we are neuroscience pioneers. Biogen discovers, develops, and delivers innovative therapies for people suffering from severe neurological and neurodegenerative diseases, as well as related therapeutic adjacencies, around the world. Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel prize winners Walter Gilbert and Phillip Sharp as one of the world's first major biotechnology firms. Biogen currently has the leading portfolio of medicines for the treatment of multiple sclerosis, is the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease, and dementia, neuromuscular disorders, movement disorders, ophthalmology, and neuropsychiatry. About Ginkgo Bioworks Ginkgo is building a platform for program cells in the same way as we program machines. The platform is enabling the growth of biotechnology across a wide range of markets, from food and agriculture to industrial chemicals and pharmaceuticals. Ginkgo is also closely involved in a variety of COVID-19 response efforts, such as community testing, epidemiological tracing, vaccine development, and therapeutics discovery.

Read More